Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Aug 2019 02:17 PM
RNS
Sareum notes Sierra Q2 results
29 Jul 2019 04:29 PM
RNS
Additional disclosure concerning Michael Owen
28 Jun 2019 07:00 AM
RNS
Additional Funds Raised
27 Jun 2019 01:50 PM
RNS
Sierra seeks strategic options for SRA737
26 Jun 2019 07:00 AM
RNS
Successful Fundraising
25 Jun 2019 04:31 PM
RNS
PrimaryBid.com Offer
25 Jun 2019 04:30 PM
RNS
Placing to progress TYK2/JAK1 programmes
13 Jun 2019 07:00 AM
RNS
Portfolio Update
03 Jun 2019 04:00 PM
RNS
Key takeaways from SRA737 webcast at ASCO
03 Jun 2019 11:05 AM
RNS
Second Price Monitoring Extn
03 Jun 2019 11:00 AM
RNS
Price Monitoring Extension
03 Jun 2019 07:00 AM
RNS
Positive SRA737 data presented at ASCO
16 May 2019 07:00 AM
RNS
ASCO abstracts for SRA737 published
08 May 2019 12:41 PM
RNS
Sareum notes Sierra Oncology Q1 2019 Results
30 Apr 2019 07:00 AM
RNS
Sareum to Present at BioTrinity 2019 in London
23 Apr 2019 07:00 AM
RNS
SRA737 Phase I/IIa data to be presented at ASCO
02 Apr 2019 07:00 AM
RNS
Preclinical Data for SRA737 Presented at AACR 2019
12 Mar 2019 07:00 AM
RNS
Sareum Holdings PLC Issue of Options
04 Mar 2019 07:00 AM
RNS
HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018
28 Feb 2019 02:04 PM
RNS
Sierra Oncology has reported its 2018 Results
28 Feb 2019 08:14 AM
RNS
New SRA737 preclin data to be presented at AACR
23 Jan 2019 01:38 PM
RNS
Sierra Oncology to present SRA737 at DDR Tx Summit
18 Dec 2018 12:35 PM
RNS
Results of AGM
18 Dec 2018 07:00 AM
RNS
AGM Statement
30 Nov 2018 11:17 AM
RNS
Amendment to Preclinical Efficacy Announcement
30 Nov 2018 07:45 AM
RNS
Preclinical Efficacy for Immunotherapy Combination
15 Nov 2018 10:24 AM
RNS
Preclinical Data for SRA737 in Ovarian Cancer
14 Nov 2018 07:00 AM
RNS
AGM NOTICE
13 Nov 2018 07:00 AM
RNS
Directorate Change
08 Nov 2018 12:28 PM
RNS
Sierra Oncology Q3 2018 Results
26 Oct 2018 07:00 AM
RNS
Completion of Placing
01 Oct 2018 07:00 AM
RNS
FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
27 Sep 2018 01:03 PM
RNS
Notice of Results
26 Sep 2018 07:00 AM
RNS
TYK2/JAK1 selected for certain cancers
11 Sep 2018 07:00 AM
RNS
Pre-Close Trading Statement
10 Sep 2018 07:00 AM
RNS
Selection of TYK2/JAK1 for autoimmune diseases
09 Aug 2018 01:15 PM
RNS
Sareum notes Sierra Oncology Q2 2018 Results
11 Jul 2018 09:38 AM
RNS
Notification of PCA Shareholding
15 Jun 2018 07:00 AM
RNS
Advisers
31 May 2018 07:00 AM
RNS
Sareum regains rights to Aurora+FLT3 inhibitors
10 May 2018 12:21 PM
RNS
SRA737 trial update in Sierra Oncology Q1 Results
24 Apr 2018 07:00 AM
RNS
Sareum to Present at BioTrinity 2018 in London
17 Apr 2018 12:45 PM
RNS
AACR 2018 Update
15 Mar 2018 07:00 AM
RNS
Late-breaker abstract for SRA737 accepted for AACR
13 Mar 2018 07:00 AM
RNS
Interim Results
27 Feb 2018 12:50 PM
RNS
Sierra Oncology expands SRA737 development program
22 Feb 2018 07:00 AM
RNS
Preclinical synergy of sra737 and PARP inhibitor
13 Feb 2018 07:00 AM
RNS
Notice of Interim Results
20 Dec 2017 11:00 AM
RNS
Issue of Options
19 Dec 2017 07:00 AM
RNS
Patent Grants in Japan & China for TYK2 Inhibitors

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

SAR share price listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings